Exclusivity Patents and exclusivity Drug Information Prescribing and other information DMFs Type 2 master files Databases Free access to database search 21 CFR FDA regulations for this API Federal Register FR search results for this API Drug Recalls For Rx's using this API

FDA Approval Activities for this Drug… VIRACEPT (nelfinavir mesylate) Tablets, 625 mg, Agouron NDA 21-503 4/30/03 | VIRACEPT (nelfinavir mesylate) Tablets and Powder, 250mg & 50mg/g Agouron NDA 20-779/S41 20-778/S20 & 21-503/S2 8/22/03 8/28/03 8/28/03 | VIRACEPT (nelfinavir mesylate) Tablets and Powder, 250mg & 50mg/g Agouron NDA 20-779/S22 4/23/03 | VIRACEPT (nelfinavir mesylate) Tablets and Powder, 250mg & 50mg/g Agouron NDA 20-778/S18 & 20-779/S39 | 12/20/02 7/30/03 4/4/03 | VIRACEPT (nelfinavir mesylate) Tablets and Powder, 250mg & 50mg/g Agouron NDA 20-778/S16, 20-778/S17, 20-779/S37 & 20-779/S38 2/5/02 4/17/02 | VIRACEPT (nelfinavir mesylate) Tablets and Powder, 250mg & 50mg/g Agouron NDA 20-778/S14, 20-779/S32 | VIRACEPT (nelfinavir mesylate) Tablets and Oral Powder, Pfizer Inc. Viracept (nelfinavir mesylate) 250 mg tablets, Pfizer | | Viracept (nelfinavir mesylate) 625 mg tablets, Pfizer | Viracept (nelfinavir mesylate) oral powder, Pfizer | VIRACEPT (nelfinavir mesylate) oral powder, Pfizer Inc., Labeling Revision | VIRACEPT (nelfinavir mesylate 250mg) tablets, Pfizer Inc., Labeling Revision | VIRACEPT (nelfinavir mesylate 625mg) tablets, Pfizer Inc., Labeling Revision Check the most up-to-date list of FDA Approvals.   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | FindingHealthOnline © 2008 Betterchem.com